On June 25, 2019, BenchSci announced an additional investment from Google’s Gradient Ventures increasing its funding to $27.2 million. This investment will be used to expand BenchSci’s team and office to meet the growing demand from pharmaceutical companies for its biomedical AI technology.
BenchSci is a biomedical artificial intelligence (AI) technology company based in Toronto, and the world leader in AI-assisted antibody selection. BenchSci’s biomedical AI technology allows scientists to run more successful experiments to accelerate drug discovery.
Gradient Ventures is Google’s AI-focused venture fund. By investing and connecting early-stage startups with Google’s resources, innovation, and technical leadership in artificial intelligence, they are able to assist founders build transformational AI companies.
Osler, Hoskin & Harcourt LLP advised BenchSci with a team led by Chad Bayne and consisting of Justin Dharamdial, Gary Marshall, Jeremy Lin and Sahil Chopra (Emerging & High Growth Companies).